ENGAGE AF-TIMI 48试验:艾多沙班与华法林在瓣膜性心脏病合并房颤患者中的比较
ENGAGE AF-TIMI 48试验的事后分析比较了合并瓣膜性心脏病(VHD)的房颤患者使用艾多沙班或华法林的结局。与无VHD患者相比,VHD患者卒中/系统性栓塞事件率相似,但死亡、主要不良心血管事件和严重出血风险更高;高剂量艾多沙班方案在VHD患者中的相对疗效与安全性同华法林相比与无VHD患者相似,无显著交互作用。
要点
- VHD患者较无VHD患者死亡风险高(HR 1.40),主要不良心血管事件(HR 1.29)和严重出血(HR 1.21)风险也更高。
- VHD患者卒中/系统性栓塞事件率与无VHD患者相似。
- 高剂量艾多沙班 vs 华法林在VHD与无VHD患者中的相对疗效和安全性无显著交互作用。
核心结论
- VHD的存在增加了死亡、主要不良心血管事件和严重出血的风险,但不影响高剂量艾多沙班相较于华法林在房颤患者中的相对疗效或安全性。
研究设计与样本
- ENGAGE AF-TIMI 48试验的事后分析,比较合并或不合并VHD的房颤患者使用艾多沙班或华法林的结局。
- VHD定义为至少中度主动脉瓣/二尖瓣反流、主动脉瓣狭窄或既往瓣膜手术(生物瓣置换、瓣膜修复、瓣膜成形术)的病史或基线超声心动图证据。
- 排除中重度二尖瓣狭窄或机械瓣患者。
- VHD患者2824例,无VHD患者18222例。
- 采用校正Cox比例风险模型比较卒中/系统性栓塞事件、严重出血及其他疗效和安全性结局。
主要发现
- 校正多变量基线特征后,与无VHD患者(n=18222)相比,VHD患者(n=2824)的卒中/系统性栓塞事件率相似。
- VHD患者死亡风险更高(HR 1.40;95%CI 1.26-1.56;p<0.001)。
- VHD患者主要不良心血管事件风险更高(HR 1.29;95%CI 1.16-1.43;p<0.001)。
- VHD患者严重出血风险更高(HR 1.21;95%CI 1.03-1.42;p=0.02)。
- 高剂量艾多沙班 vs 华法林:VHD患者卒中/系统性栓塞事件HR 0.69(95%CI 0.44-1.07),无VHD患者HR 0.91(95%CI 0.77-1.07),交互作用p=0.26。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of non-vitamin K antagonist oral anticoagulants (NOACs) instead of vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular heart disease (VHD) is of substantial interest. OBJECTIVES: This study explored outcomes in patients with AF with and without VHD in the ENGAGE AF-TIMI 48 (Effective Anticoagulation with factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial, comparing edoxaban with warfarin. METHODS: Valvular heart disease was defined as history or baseline echocardiography evidence of at least moderate aortic/mitral regurgitation, aortic stenosis, or prior valve surgery (bioprosthesis replacement, valve repair, valvuloplasty). Patients with moderate to severe mitral stenosis or mechanical heart valves were excluded from the trial. Comparisons were made of rates of stroke/systemic embolic event (SSEE), major bleeding, additional efficacy and safety outcomes, as well as net clinical outcomes, in patients with or without VHD treated with edoxaban or warfarin, using adjusted Cox proportional hazards. RESULTS: After adjustment for multiple baseline characteristics, compared with no-VHD patients (n = 18,222), VHD patients (n = 2,824) had a similar rate of SSEE but higher rates of death (hazard ratio [HR]: 1.40; 95% confidence interval [CI]:1.26 to 1.56; p <0.001), major adverse cardiovascular events (HR: 1.29; 95% CI: 1.16 to 1.43; p <0.001), and major bleeding (HR: 1.21; 95% CI: 1.03 to 1.42; p = 0.02). Higher-dose edoxaban regimen had efficacy similar to warfarin in the presence of VHD (for SSEE, HR: 0.69; 95% CI: 0.44 to 1.07, in patients with VHD, and HR: 0.91; 95% CI: 0.77 to 1.07, in patients without VHD; p interaction [pint] = 0.26; and for less major bleeding, HR: 0.74; 95% CI: 0.53 to 1.02 in patients with VHD, and HR: 0.82; 95% CI: 0.71 to 0.94, in patients with no VHD; pint = 0.57). CONCLUSIONS: The presence of VHD increased the risk of death, major adverse cardiovascular events, and major bleeding but did not affect the relative efficacy or safety of higher-dose edoxaban versus warfarin in AF. (Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs. Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391).
引用
- De Caterina R, Renda G, Carnicelli AP, et al. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol. 2017. PMID: 28302288. doi:10.1016/j.jacc.2016.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。